Side-by-side comparison of AI visibility scores, market position, and capabilities
Science-led synbiotic brand with $56M revenue, profitable, and ranking top-5 on Amazon; clinically backed DS-01 Daily Synbiotic sold at Target nationwide; expanding into AI-driven microbiome research beyond its consumer supplement products.
Seed Health is a Los Angeles-based microbial sciences company founded in 2018 by Ara Katz and Raja Dhir. The company is best known for its DS-01 Daily Synbiotic, a two-in-one probiotic and prebiotic capsule developed in partnership with academic researchers. Seed has raised approximately $44 million in total funding, with a Series A led by The Craftory, and has achieved profitability.\n\nThe company reported approximately $56 million in revenue with 500%+ growth over three years, ranking among Amazon's top-five probiotic supplements and selling in Target stores nationwide. Seed differentiates itself by emphasizing clinical research transparency — each strain is backed by published studies, and the brand has become a go-to reference among health-conscious consumers and clinicians.\n\nBeyond consumer products, Seed operates a scientific research arm called SeedLabs that conducts microbiome research in areas including planetary health and pediatric immunity. In 2024, the company announced an AI-powered initiative to accelerate strain discovery. This dual consumer-science identity gives Seed unusual credibility in a supplement category often criticized for weak evidence.
AI quality assurance with insurance-backed warranties from Swiss Re and Greenlight Re; EU AI Act compliance assessments backed by YC and reinsurance partners for high-risk AI deployments.
Armilla AI is a third-party AI quality assurance and warranty company that evaluates AI models for organizations deploying AI in regulated or high-stakes contexts — assessing models against EU AI Act and NIST AI Risk Management Framework requirements for risks including bias, hallucination, robustness failures, and adversarial vulnerabilities, then providing performance guarantees backed by insurance coverage from reinsurers Swiss Re, Greenlight Re, and Chaucer. Founded in Toronto, Canada, Armilla raised $6.81 million total including a C$4.5 million seed round in February 2024 from Mistral Venture Partners, MS&AD Ventures, Y Combinator, and its reinsurance partners.\n\nArmilla's model is unique in the AI governance market — rather than just providing compliance reports, Armilla backs its assessments with insurance warranty products. An enterprise deploying a third-party AI model can purchase an Armilla warranty that pays out if the model performs differently than assessed (fails on bias, accuracy, or robustness metrics), transferring AI performance risk to insurance markets that can price and distribute it. This insurance mechanism creates financial accountability for AI quality claims that audit reports alone don't provide.\n\nIn 2025, Armilla competes in the AI governance, risk, and compliance market with Credo AI, Arthur AI, and AI audit firms for enterprise AI risk assessment and compliance tools. The EU AI Act, fully applicable by August 2025 for high-risk AI systems, is driving enterprise compliance urgency — companies deploying AI in hiring, credit scoring, healthcare, and other regulated contexts need third-party conformity assessments. Armilla's insurance-backed warranty differentiates its offering from pure advisory competitors. The reinsurer backing (Swiss Re, Greenlight Re, Chaucer) provides both capital credibility and distribution through insurance broker channels. The 2025 strategy focuses on growing EU AI Act compliance assessments and expanding the warranty product coverage to more AI deployment use cases.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.